local_hospital

Thoraxklinik Heidelberg gGmbH

Address
lock Available on a paid plan

Thoraxonkologie Heidelberg - Neoplasms

Clinical research at Thoraxklinik Heidelberg gGmbH is strongly focused on cancer, especially lung cancer and related thoracic tumors. Studies are examining whether newer treatment combinations can improve survival, slow disease progression, and offer better options for patients with advanced or previously treated disease.

  • Small cell lung cancer and extensive-stage small-cell lung cancer
  • Non-Small Cell Lung Cancer (NSCLC), including metastatic and c-Met overexpressing forms
  • Pleural mesothelioma, neuroendocrine carcinoma, and other aggressive thoracic cancers

These trials are mainly testing new therapies and comparing them with current standards of care to find more effective approaches for hard-to-treat thoracic malignancies.

Respiratory Tract Diseases

The site also supports important studies in respiratory disease, with a particular emphasis on chronic and progressive lung conditions. Research here is aimed at improving breathing capacity, preserving lung function, and easing the long-term impact of serious pulmonary illness.

  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Pulmonary arterial hypertension and related forms of PAH
  • Trials assessing symptom control, exercise tolerance, and disease progression

At this Heidelberg hospital, the goal is to evaluate new treatments that may better manage debilitating lung diseases and improve day-to-day function for patients.

Cardiovascular Diseases and Pulmonary Vascular Research

Another key area of research involves pulmonary vascular disease, bridging cardiovascular and respiratory medicine. The studies are centered on pulmonary arterial hypertension, where investigators are looking for therapies that can reduce disease burden and improve physical capacity.

  • Pulmonary arterial hypertension in multiple patient groups
  • Measures of exercise ability and vascular resistance
  • Evaluation of treatment effectiveness in a chronic, high-impact condition

These trials reflect a broader effort to advance care for patients with serious cardiopulmonary disorders through better disease control and functional outcomes.

Site Overview

assignment
133
connected trials
corporate_fare
59
sponsors
science
153
IMPs

Activity Indicator

Last 6 months

16
Trials started
+14% vs previous period.
14
Trials started 6–12 months ago
133
Total trials linked
Highly Active
trending_upGrowing+14%
3
3
3
4
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 5 therapeutic areas and 15 of 153 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 150 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
59
Sponsors (total)
59
Active sponsors
32

Sponsor Network

Top 32 by active trials.

lock +31 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +24 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
133
Outperforms 98% of sites
public
Therapeutic diversity
5areas
Outperforms 89% of sites
groups
Sponsor diversity
59sponsors
Outperforms 98% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Thoraxklinik Heidelberg gGmbH

lock Showing 1 of 133 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)Rein Therapeutics Inc.Phase IIRecruitingApr 2026

IMP list

lock Showing 1 of 153 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Carboplatin31Unknown2018-08-092026-06-23

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.